Literature DB >> 10400767

Reverse transcriptase inhibitors can selectively block the synthesis of differently sized viral DNA transcripts in cells acutely infected with human immunodeficiency virus type 1.

Y Quan1, L Rong, C Liang, M A Wainberg.   

Abstract

We have recently reported that the in vitro inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcription by inhibitors of reverse transcriptase (RT) occurred most efficiently when the expected DNA products of RT reactions were long (Quan et al. , Nucleic Acids Res. 26:5692-5698, 1998). Here, we have used a quantitative PCR to analyze HIV-1 reverse transcription within acutely infected cells treated with RT inhibitors. We found that levels of minus-strand strong-stop DNA [(-)ssDNA] formed in acutely infected MT2 cells were only slightly reduced if cells were infected with viruses that had been generated in the presence of either azidothymidine or nevirapine (5 microM) and maintained in the presence of this drug throughout the viral adsorption period and thereafter. Control experiments in which virus inoculation of cells was performed at 4 degrees C, followed directly by cell extraction, showed that less than 1% of total (-)ssDNA within acutely infected cells was attributable to its presence within adsorbed virions. In contrast, synthesis of intermediate-length reverse-transcribed DNA products decreased gradually as viral DNA strand elongation took place in the presence of either of these inhibitors. This establishes that nucleoside and nonnucleoside RT inhibitors can exert similar temporal impacts in regard to inhibition of viral DNA synthesis. Generation of full-length viral DNA, as expected, was almost completely blocked in the presence of these antiviral drugs. These results provide insight into the fact that high concentrations of drugs are often needed to yield inhibitory effects in cell-free RT assays performed with short templates, whereas relatively low drug concentrations are often strongly inhibitory in cellular systems.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10400767      PMCID: PMC112754     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Identification of sequences downstream of the primer binding site that are important for efficient replication of human immunodeficiency virus type 1.

Authors:  X Li; C Liang; Y Quan; R Chandok; M Laughrea; M A Parniak; L Kleiman; M A Wainberg
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Human immunodeficiency virus reverse transcriptase: steady-state and pre-steady-state kinetics of nucleotide incorporation.

Authors:  J E Reardon
Journal:  Biochemistry       Date:  1992-05-12       Impact factor: 3.162

3.  The observed inhibitory potency of 3'-azido-3'-deoxythymidine 5'-triphosphate for HIV-1 reverse transcriptase depends on the length of the poly(rA) region of the template.

Authors:  Q F Ma; I C Bathurst; P J Barr; G L Kenyon
Journal:  Biochemistry       Date:  1992-02-11       Impact factor: 3.162

Review 4.  Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo.

Authors:  R S Goody; B Müller; T Restle
Journal:  FEBS Lett       Date:  1991-10-07       Impact factor: 4.124

5.  Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates.

Authors:  Y Quan; Z Gu; X Li; C Liang; M A Parniak; M A Wainberg
Journal:  J Mol Biol       Date:  1998-03-27       Impact factor: 5.469

6.  Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

Authors:  N K Back; M Nijhuis; W Keulen; C A Boucher; B O Oude Essink; A B van Kuilenburg; A H van Gennip; B Berkhout
Journal:  EMBO J       Date:  1996-08-01       Impact factor: 11.598

7.  Enhanced impairment of chain elongation by inhibitors of HIV reverse transcriptase in cell-free reactions yielding longer DNA products.

Authors:  Y Quan; C Liang; P Inouye; M A Wainberg
Journal:  Nucleic Acids Res       Date:  1998-12-15       Impact factor: 16.971

8.  HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.

Authors:  J A Zack; S J Arrigo; S R Weitsman; A S Go; A Haislip; I S Chen
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

9.  Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle.

Authors:  J A Zack; A M Haislip; P Krogstad; I S Chen
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

10.  Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression.

Authors:  S Y Kim; R Byrn; J Groopman; D Baltimore
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

View more
  14 in total

1.  Impact of human immunodeficiency virus type 1 RNA dimerization on viral infectivity and of stem-loop B on RNA dimerization and reverse transcription and dissociation of dimerization from packaging.

Authors:  N Shen; L Jetté; C Liang; M A Wainberg; M Laughrea
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Timing of the components of the HIV life cycle in productively infected CD4+ T cells in a population of HIV-infected individuals.

Authors:  John M Murray; Anthony D Kelleher; David A Cooper
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

3.  A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.

Authors:  Michael E Abram; Manuel Tsiang; Kirsten L White; Christian Callebaut; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

4.  Blood-Derived CD4 T Cells Naturally Resist Pyroptosis during Abortive HIV-1 Infection.

Authors:  Isa Muñoz-Arias; Gilad Doitsh; Zhiyuan Yang; Stefanie Sowinski; Debbie Ruelas; Warner C Greene
Journal:  Cell Host Microbe       Date:  2015-10-14       Impact factor: 21.023

5.  Feline immunodeficiency virus cell entry.

Authors:  S C Frey; E A Hoover; J I Mullins
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

6.  Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Fernando A Frankel; Bruno Marchand; Dan Turner; Matthias Götte; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

7.  Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation.

Authors:  Yudong Quan; Bluma G Brenner; Maureen Oliveira; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

Review 8.  Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors.

Authors:  Nicolas Sluis-Cremer; Gilda Tachedjian
Journal:  Virus Res       Date:  2008-03-26       Impact factor: 3.303

9.  Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.

Authors:  Paul L Boyer; Stefan G Sarafianos; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Early detection of a two-long-terminal-repeat junction molecule in the cytoplasm of recombinant murine leukemia virus-infected cells.

Authors:  Fatima Serhan; Magalie Penaud; Caroline Petit; Thierry Leste-Lasserre; Stéphane Trajcevski; David Klatzmann; Ghislaine Duisit; Pierre Sonigo; Philippe Moullier
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.